Stockholders' Equity (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 81 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Apr. 05, 2023 |
Apr. 30, 2023 |
Jan. 31, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Oct. 10, 2028 |
Dec. 15, 2022 |
|
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Par value per share (in Dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
| Stock issued during period, shares, purchase of assets (in Shares) | 400,000 | |||||||||||
| Aggregate shares (in Shares) | 1,170,680 | |||||||||||
| Warrants purchase price (in Dollars per share) | $ 1.78 | |||||||||||
| Company’s outstanding common stock percent | 9.99% | |||||||||||
| Prefunded Warrant Exercised | $ 117 | |||||||||||
| Assess change in relative fair value, description | To assess for the change in relative fair value, the Company performed a Black Scholes Option Model calculation to quantify the fair value of the common warrants under their original terms as of the modification date using the following assumptions: a share price of $1.43, exercise prices of $21.20 and $3.50 for the July 2022 common warrants and December 2022 common warrants, respectively, an expected term of 4.8 and 5.2 years, respectively, volatility of 106%, a dividend rate of 0% and a discount rate of 3.36. The Company then performed a Black Scholes Option Model calculation to quantify the fair value of the common warrants with their new modified terms as of the modification date using the following assumptions: a share price of $1.43, an exercise price of $1.78 for both the July 2022 common warrants and December 2022 common warrants, an expected term of 5.5 years, volatility of 106%, a dividend rate of 0% and a discount rate of 3.36. The aggregate difference of approximately $0.8 million between the two calculated amounts was recorded as an equity issuance cost within equity during the period to account for the change in relative fair value. | |||||||||||
| Restricted Stock (in Shares) | 3,645 | 1,601,864 | ||||||||||
| Amortization of restricted stock shares | $ 8,100 | $ 14,175 | ||||||||||
| Gain (loss) on settlement of liabilities | $ 551,310 | |||||||||||
| Research and development expenses | $ 144,410 | 226,181 | ||||||||||
| General and administrative expenses | 0 | $ 0 | 0 | $ 5,261 | ||||||||
| Compensation expense | 855,679 | |||||||||||
| Common Stock [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Aggregate shares (in Shares) | 400,000 | |||||||||||
| Research and development expenses | 80,607 | 167,325 | ||||||||||
| General and administrative expenses | $ 470,703 | 941,406 | ||||||||||
| Stock Options [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Unrecognized stock-based compensation expense | 2,433,755 | |||||||||||
| Restricted Stock [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Unrecognized stock-based compensation expense | $ 6,075 | |||||||||||
| Weighted average remaining vesting period | 6 months | |||||||||||
| Research and Development Expense [Member] | Common Stock [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Research and development expenses | $ 1,108,731 | |||||||||||
| General and Administrative Expense [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| General and administrative expenses | $ 711,264 | $ 1,375,673 | ||||||||||
| Pre-Funded Warrants (Member) | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Aggregate shares (in Shares) | 1,570,680 | |||||||||||
| Warrants purchase price (in Dollars per share) | $ 1.91 | |||||||||||
| Aggregate gross proceeds | $ 3,000,000 | |||||||||||
| Pre-Funded Warrant Shares (in Shares) | 1,170,680 | |||||||||||
| Warrant Price [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Warrants purchase price (in Dollars per share) | $ 0.0001 | $ 21.2 | $ 3.5 | $ 1.78 | ||||||||
| Warrant to Purchase Common Stock [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Warrants purchase (in Shares) | 306,604 | 2,571,429 | ||||||||||
| Restricted Stock [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Restricted Stock (in Shares) | 11,745 | |||||||||||
| Common Warrant [Member] | ||||||||||||
| Stockholders' Equity (Details) [Line Items] | ||||||||||||
| Company’s outstanding common stock percent | 9.99% | |||||||||||